Compare CRDF & CBAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDF | CBAN |
|---|---|---|
| Founded | 1999 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 429.7M |
| IPO Year | 2012 | 1995 |
| Metric | CRDF | CBAN |
|---|---|---|
| Price | $0.90 | $19.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.14 | ★ $25.13 |
| AVG Volume (30 Days) | ★ 968.3K | 134.1K |
| Earning Date | 11-12-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | ★ 27.37 | 16.91 |
| EPS | N/A | ★ 1.40 |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | $27.95 |
| Revenue Next Year | N/A | $34.25 |
| P/E Ratio | ★ N/A | $14.33 |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $0.71 | $16.29 |
| 52 Week High | $3.31 | $22.46 |
| Indicator | CRDF | CBAN |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 40.27 |
| Support Level | $0.77 | $19.44 |
| Resistance Level | $1.13 | $20.95 |
| Average True Range (ATR) | 0.07 | 0.52 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 70.33 | 15.87 |
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.